Related Experiment Video

Updated: Aug 15, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

New approaches to drug development in pediatric oncology

Peter C Adamson1, Susan M Blaney

  • 1The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. adamsonp@mail.med.upenn.edu

Cancer Journal (Sudbury, Mass.)
|October 4, 2005
PubMed

Insights

New strategies are needed to improve outcomes for pediatric cancers, especially poor-prognosis tumors. Research focuses on targeted drugs and understanding genetic variations to enhance childhood cancer treatment effectiveness and reduce side effects.

Area of Science:

  • Pediatric Oncology
  • Pharmacology
  • Cancer Genomics

Background:

  • Childhood cancer treatment has advanced significantly over 50 years.
  • Progress in treating some childhood cancers remains limited, necessitating new therapeutic approaches.
  • Minimizing long-term side effects of cancer therapy is a critical goal.

Purpose of the Study:

  • To review the evolving landscape of new drug development for pediatric malignancies.
  • To highlight the need for improved strategies for poor-prognosis childhood tumors.
  • To emphasize the importance of reducing treatment-related sequelae in children.

Main Methods:

  • Review of current pediatric-specific drug development initiatives.
  • Discussion of research into the molecular heterogeneity of childhood tumors.
  • Examination of investigations into genetic factors influencing drug response.

Main Results:

  • A pediatric-specific preclinical drug testing initiative is proposed.
  • Understanding molecular heterogeneity can guide the development of targeted therapies.
  • Investigating genetic variability is crucial for personalized treatment.

Conclusions:

  • New drug development strategies are essential for advancing childhood cancer care.
  • Targeted therapies and personalized medicine hold promise for improving outcomes.
  • Reducing the long-term impact of treatment is a key objective for future research.

More Related Videos

A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells06:32

A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells

Published on: June 26, 2026

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...